• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
	Q3-CY2026	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014
Balance Sheet Date			2026-Apr-30	2026-Jan-31	2025-Oct-31	2025-Jul-31	2025-Apr-30	2025-Jan-31
Fiscal Period			Q4-FY2026	Q3-FY2026	Q2-FY2026	Q1-FY2026	Q4-FY2025	Q3-FY2025
Total Revenue			28,638,000$	24,552,000$	22,565,000$	19,371,000$	17,233,000$	15,090,000$	14,710,000$	12,782,000$
QoQ%			16.64%	8.81%	16.49%	12.41%	14.20%	2.58%	15.08%
YoY%			66.18%	62.70%	53.40%	51.55%
Cost Of Revenue			12,956,000$	11,646,000$	11,141,000$	10,520,000$	9,600,000$	8,543,000$	8,880,000$	8,582,000$
Gross Profit			15,682,000$	12,906,000$	11,424,000$	8,851,000$	7,633,000$	6,547,000$	5,830,000$	4,200,000$
Gross Margin			54.76%	52.57%	50.63%	45.69%	44.29%	43.39%	39.63%	32.86%
Operating Expenses			55,026,000$	47,671,000$	43,179,000$	37,729,000$	55,845,000$	27,148,000$	24,964,000$	22,631,000$
Operating Income			(39,344,000$)	(34,765,000$)	(31,755,000$)	(28,878,000$)	(48,212,000$)	(20,601,000$)	(19,134,000$)	(18,431,000$)
Operating Margin			(137.38%)	(141.60%)	(140.73%)	(149.08%)	(279.77%)	(136.52%)	(130.08%)	(144.20%)
Interest Income			2,226,000$	2,163,000$	1,796,000$	2,167,000$	1,656,000$	628,000$	878,000$	37,000$
Interest Expenses
Income Before Tax			(38,643,000$)	(34,131,000$)	(32,751,000$)	(25,793,000$)	(51,009,000$)	(21,741,000$)	(20,613,000$)	(20,316,000$)
Tax Expenses			192,000$	35,000$	34,000$	33,000$	102,000$	18,000$	8,000$	7,000$
Net Income			(38,835,000$)	(34,166,000$)	(32,785,000$)	(25,826,000$)	(51,111,000$)	(21,759,000$)	(20,621,000$)	(20,323,000$)
Profit Margin			(135.61%)	(139.16%)	(145.29%)	(133.32%)	(296.59%)	(144.20%)	(140.18%)	(159.00%)
TTM			(138.36%)	(171.87%)	(177.06%)	(179.68%)	(190.28%)
Earnings to Minority							4,233,000$	(250,000$)	(253,000$)	(439,000$)
Earnings to Common Shareholders			(38,835,000$)	(34,166,000$)	(32,785,000$)	(25,826,000$)	(55,344,000$)	(24,833,000$)	(23,691,000$)	(22,267,000$)
QoQ%			(13.67%)	(4.21%)	(26.95%)	53.34%	(122.87%)	(4.82%)	(6.40%)
YoY%			29.83%	(37.58%)	(38.39%)	(15.98%)
Earnings Per Share, Basic			(0.67$)	(0.61$)	(0.64$)	(0.50$)	(1.43$)	(1.25$)	(1.19$)	(1.12$)
Earnings Per Share, Diluted			(0.67$)	(0.61$)	(0.64$)	(0.50$)	(1.43$)	(1.25$)	(1.19$)	(1.12$)
Unlevered FCF Per Share, Basic			(0.49$)	(0.50$)	(0.50$)	(0.67$)	(0.81$)	(1.11$)	(1.13$)	(1.23$)
Unlevered FCF Per Share, Diluted			(0.49$)	(0.50$)	(0.50$)	(0.67$)	(0.81$)	(1.11$)	(1.13$)	(1.23$)
Average Shares, Basic			58,209,502	55,848,413	51,376,278	51,304,599	38,678,834	19,885,382	19,885,382	19,885,382
Average Shares, Diluted			58,209,502	55,848,413	51,376,278	51,304,599	38,678,834	19,885,382	19,885,382	19,885,382
EBIT			(38,643,000$)	(34,131,000$)	(32,751,000$)	(25,793,000$)	(51,009,000$)	(21,741,000$)	(20,613,000$)	(20,316,000$)
EBITDA			(36,318,000$)	(32,148,000$)	(30,378,000$)	(23,765,000$)	(49,173,000$)	(19,853,000$)	(18,744,000$)	(17,941,000$)

Copy Table ✓